Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Glucotrack, Inc.IGAP · Entity 8422 | Director · Chief Executive Officer | March 20, 2017 | March 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Glucotrack, Inc.
Report date March 20, 2017 · Filed March 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2027-03-20 | Direct | 1,673,996 |
Reported balance
After 2017-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-20 · Grant · Acquired 1,673,996 · Balance 1,673,996 F1: The options will vest in equal monthly installments over a three year period commencing on March 20, 2017. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.41 · Expires 2027-03-20 | Direct | 559,414 |
Reported balance
After 2017-03-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-20 · Grant · Acquired 559,414 · Balance 559,414 F1: The options will vest in equal monthly installments over a three year period commencing on March 20, 2017. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.75 · Expires 2027-03-20 | Direct | 844,130 |
Reported balance
After 2017-03-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-20 · Grant · Acquired 844,130 · Balance 844,130 F1: The options will vest in equal monthly installments over a three year period commencing on March 20, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in equal monthly installments over a three year period commencing on March 20, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2017 Filed Mar 22, 2017 21:44 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOption (Right to Buy) · Derivative | 844,130 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001178913-17-000855 · zk1719718.xml · derivative · entry 3 GRAHAM JOHN A · CIK 0001701726 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 844,130 Underlying: Common Stock, par value $0.001 per share · 844,130 shares Expires 2027-03-20 F1 · derivative.exercise_date: The options will vest in equal monthly installments over a three year period commencing on March 20, 2017. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 21:44 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOption (Right to Buy) · Derivative | 559,414 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001178913-17-000855 · zk1719718.xml · derivative · entry 2 GRAHAM JOHN A · CIK 0001701726 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,414 Underlying: Common Stock, par value $0.001 per share · 559,414 shares Expires 2027-03-20 F1 · derivative.exercise_date: The options will vest in equal monthly installments over a three year period commencing on March 20, 2017. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 21:44 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOption (Right to Buy) · Derivative | 1,673,996 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001178913-17-000855 · zk1719718.xml · derivative · entry 1 GRAHAM JOHN A · CIK 0001701726 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,673,996 Underlying: Common Stock, par value $0.001 per share · 1,673,996 shares Expires 2027-03-20 F1 · derivative.exercise_date: The options will vest in equal monthly installments over a three year period commencing on March 20, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.